136 related articles for article (PubMed ID: 35238407)
1. Alginates for Protection Against Pepsin-Acid Induced Aerodigestive Epithelial Barrier Disruption.
Samuels TL; Yan K; Patel N; Plehhova K; Coyle C; Hurley BP; Johnston N
Laryngoscope; 2022 Dec; 132(12):2327-2334. PubMed ID: 35238407
[TBL] [Abstract][Full Text] [Related]
2. Topical Alginate Protection against Pepsin-Mediated Esophageal Damage: E-Cadherin Proteolysis and Matrix Metalloproteinase Induction.
Samuels TL; Blaine-Sauer S; Yan K; Plehhova K; Coyle C; Johnston N
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175640
[TBL] [Abstract][Full Text] [Related]
3. Randomised clinical trial: the clinical efficacy and safety of an alginate-antacid (Gaviscon Double Action) versus placebo, for decreasing upper gastrointestinal symptoms in symptomatic gastroesophageal reflux disease (GERD) in China.
Sun J; Yang C; Zhao H; Zheng P; Wilkinson J; Ng B; Yuan Y
Aliment Pharmacol Ther; 2015 Oct; 42(7):845-54. PubMed ID: 26228097
[TBL] [Abstract][Full Text] [Related]
4. Review article: alginate-raft formulations in the treatment of heartburn and acid reflux.
Mandel KG; Daggy BP; Brodie DA; Jacoby HI
Aliment Pharmacol Ther; 2000 Jun; 14(6):669-90. PubMed ID: 10848650
[TBL] [Abstract][Full Text] [Related]
5. Assessment and protection of esophageal mucosal integrity in patients with heartburn without esophagitis.
Woodland P; Lee C; Duraisamy Y; Farré R; Dettmar P; Sifrim D
Am J Gastroenterol; 2013 Apr; 108(4):535-43. PubMed ID: 23358463
[TBL] [Abstract][Full Text] [Related]
6. Alginate antacid (Gaviscon DA) chewable tablets reduce esophageal acid exposure in Chinese patients with gastroesophageal reflux disease and heartburn symptoms.
Yuan YZ; Fang JY; Zou DW; Levinson N; Jenner B; Wilkinson J
J Dig Dis; 2016 Nov; 17(11):725-734. PubMed ID: 27622897
[TBL] [Abstract][Full Text] [Related]
7. How many cases of laryngopharyngeal reflux suspected by laryngoscopy are gastroesophageal reflux disease-related?
de Bortoli N; Nacci A; Savarino E; Martinucci I; Bellini M; Fattori B; Ceccarelli L; Costa F; Mumolo MG; Ricchiuti A; Savarino V; Berrettini S; Marchi S
World J Gastroenterol; 2012 Aug; 18(32):4363-70. PubMed ID: 22969200
[TBL] [Abstract][Full Text] [Related]
8. The role of pepsin in the laryngopharyngeal reflux.
Kowalik K; Krzeski A
Otolaryngol Pol; 2017 Dec; 71(6):7-13. PubMed ID: 29327685
[TBL] [Abstract][Full Text] [Related]
9. Pepsin detection in patients with laryngopharyngeal reflux before and after fundoplication.
Wassenaar E; Johnston N; Merati A; Montenovo M; Petersen R; Tatum R; Pellegrini C; Oelschlager B
Surg Endosc; 2011 Dec; 25(12):3870-6. PubMed ID: 21695583
[TBL] [Abstract][Full Text] [Related]
10. Simulated reflux decreases vocal fold epithelial barrier resistance.
Erickson E; Sivasankar M
Laryngoscope; 2010 Aug; 120(8):1569-75. PubMed ID: 20564752
[TBL] [Abstract][Full Text] [Related]
11. The Protease Inhibitor Amprenavir Protects against Pepsin-Induced Esophageal Epithelial Barrier Disruption and Cancer-Associated Changes.
Blaine-Sauer S; Samuels TL; Yan K; Johnston N
Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047737
[TBL] [Abstract][Full Text] [Related]
12. The role of an alginate suspension on pepsin and bile acids - key aggressors in the gastric refluxate. Does this have implications for the treatment of gastro-oesophageal reflux disease?
Strugala V; Avis J; Jolliffe IG; Johnstone LM; Dettmar PW
J Pharm Pharmacol; 2009 Aug; 61(8):1021-8. PubMed ID: 19703345
[TBL] [Abstract][Full Text] [Related]
13. Hypopharyngeal pepsin and Sep70 as diagnostic markers of laryngopharyngeal reflux: preliminary study.
Komatsu Y; Kelly LA; Zaidi AH; Rotoloni CL; Kosovec JE; Lloyd EJ; Waheed A; Hoppo T; Jobe BA
Surg Endosc; 2015 May; 29(5):1080-7. PubMed ID: 25159637
[TBL] [Abstract][Full Text] [Related]
14. Randomised clinical trial: relief of upper gastrointestinal symptoms by an acid pocket-targeting alginate-antacid (Gaviscon Double Action) - a double-blind, placebo-controlled, pilot study in gastro-oesophageal reflux disease.
Thomas E; Wade A; Crawford G; Jenner B; Levinson N; Wilkinson J
Aliment Pharmacol Ther; 2014 Mar; 39(6):595-602. PubMed ID: 24471505
[TBL] [Abstract][Full Text] [Related]
15. Ocular Surface Disease as Extraesophageal Gastroesophageal Reflux Disease Manifestation: A Specific Therapeutic Strategy.
Di Zazzo A; Micera A; Surico PL; Balzamino BO; Luccarelli V; Antonini M; Coassin M; Bonini S
Cornea; 2024 Mar; 43(3):295-300. PubMed ID: 37404100
[TBL] [Abstract][Full Text] [Related]
16. Saliva pepsin level of laryngopharyngeal reflux patients is not correlated with reflux episodes.
Bobin F; Journe F; Lechien JR
Laryngoscope; 2020 May; 130(5):1278-1281. PubMed ID: 31461170
[TBL] [Abstract][Full Text] [Related]
17. Gaviscon® Advance alone versus co-prescription of Gaviscon® Advance and proton pump inhibitors in the treatment of laryngopharyngeal reflux.
Wilkie MD; Fraser HM; Raja H
Eur Arch Otorhinolaryngol; 2018 Oct; 275(10):2515-2521. PubMed ID: 30062580
[TBL] [Abstract][Full Text] [Related]
18. Detecting laryngopharyngeal reflux in patients with upper airways symptoms: Symptoms, signs or salivary pepsin?
Spyridoulias A; Lillie S; Vyas A; Fowler SJ
Respir Med; 2015 Aug; 109(8):963-9. PubMed ID: 26044812
[TBL] [Abstract][Full Text] [Related]
19. Oral and Inhaled Fosamprenavir Reverses Pepsin-Induced Damage in a Laryngopharyngeal Reflux Mouse Model.
Johnston N; Samuels TL; Goetz CJ; Arnold LA; Smith BC; Seabloom D; Wuertz B; Ondrey F; Wiedmann TS; Vuksanovic N; Silvaggi NR; MacKinnon AC; Miller J; Bock J; Blumin JH
Laryngoscope; 2023 Jan; 133 Suppl 1(Suppl 1):S1-S11. PubMed ID: 35678265
[TBL] [Abstract][Full Text] [Related]
20. Does Pepsin Saliva Concentration (Peptest™) Predict the Therapeutic Response of Laryngopharyngeal Reflux Patients?
Lechien JR; Bobin F; Dequanter D; Rodriguez A; Le Bon S; Horoi M; Thill MP; Salem C; Muls V; Saussez S
Ann Otol Rhinol Laryngol; 2021 Sep; 130(9):996-1003. PubMed ID: 33467863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
